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NEURODEGENERATION: THE
CEREBELLUM IS A COMMON
TARGET
The putative role of DNA repair
deficiency in the pathogenesis of
several neurological disorders has
been the subject of intense scientific scrutiny. Ataxia
telangiectasia (AT) is the prototype example of such disorders
and yet it is still not completely understood why deficiency of
the protein mutated in AT (Ataxia Telangiectasia mutated,
ATM) leads to the severe neurological abnormalities seen in AT.
Cerebellar degeneration is the most common neurological
presentation of AT, which is also a shared feature among at least
three distinct hereditary diseases: spinocerebellar ataxia with
axonal neuropathy 1 (SCAN1), ataxia oculomotor apraxia 1
(AOA1) and ataxia oculomotor apraxia 2 (AOA2). A unique
feature of the cerebellum is its extended postnatal development.
During this phase of growth rapid cell proliferation is expected
to generate replication stress leading to more DNA breaks than
in other parts of the nervous system. Whether this explains the
selective degeneration of the cerebellum in AT, SCAN1, AOA1
and AOA2 is yet to be determined.
Although SCAN1, AOA1 and AOA2 share most of the
neurological presentations, they lack the cancer predisposition
and immunodeficiency observed in AT. However, there is a fair
degree of overlap in the extra-neurological features (Fig 1). For
example, whereas AT and AOA2 patients present with high
levels of alpha fetoprotein (AFP), SCAN1 and AOA1 patients
present with reduced levels of serum albumin (Date et al, 2001;
Moreira et al, 2001; Takashima et al, 2002). It is unknown
whether this reflects a consequence of the associated DNA repair
defect or a result of a progressive functional decline. AOA2 is
associated with defects in senataxin (SETX) – a putative DNA/
RNA helicase that has been implicated in the coordination of
transcription and DNA repair (Suraweera et al, 2007, 2009).
SCAN1 and AOA1 are associated with defects in the two DNA
end-processing enzymes – tyrosyl DNA phosphodiesterase
1(TDP1) and aprataxin (APTX), respectively. Intriguingly, both
TDP1 and APTX appear to process DNA breaks that arise due to
abortive activities of endogenous enzymes: APTX is a 50-AMP
hydrolase and TDP1 is a 30-end processing enzyme that repairs
topoisomerase 1 (Top1) mediated DNA damage.
REPAIR OF TOPOISOMERASE-MEDIATED DNA
DAMAGE AND NEURODEGENERATION: SAME
PATHWAY WITH DIFFERENT CLINICAL FEATURES
DNA topoisomerases
The compact and supercoiled nature of the DNA double helix
requires topological modification during important cellular
processes, such as transcription, replication and repair. This
modification is conducted by DNA topoisomerases and involves
transient cleavage of one or both strands of DNA followed by
religation of the double helix (Champoux, 2001). This
dangerous mode of catalysis involves an intermediate structure
in which the topoisomerase is attached either to the 30-end
(Top1), or to the 50-end (Top2), via a covalent phosphotyrosyl
bond. The half-life of these intermediates in vivo is normally
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very short and breaks are sealed rapidly (Wang, 2002).
However, collision with the DNA replication machinery, RNA
polymerases or the proximity to other types of DNA lesions can
inhibit or delay religation, creating potentially deleterious
protein-linked DNA breaks. The nature of these breaks depends
on the type of the topoisomerase, the biological process
involved and on the stage of the cell cycle (Pommier et al,
2006). These protein-linked DNA breaks can interfere with
important cellular processes such as transcription, can trigger
cell death or, if repaired inaccurately, may lead to mutations.
Defects in the pathway of repairing Top1-mediated DNA breaks
have been linked to at least three distinct human neurological
disorders ranging from mental retardation (Kerzendorfer et al,
2010) and cerebellar degeneration (Takashima et al, 2002) to
microcephaly (Shen et al, 2010).
Repair of DNA topoisomerase-linked DNA breaks
Removal of the covalently linked topoisomerase from DNA is
mandatory prior to subsequent repair steps. This could be
achieved by a non-specific nucleolytic cleavage of DNA,
liberating the topoisomerase and a fragment of DNA (Connelly
& Leach, 2004). A number of nucleases have been postulated to
possess roles in this mechanism in eukaryotic cells, such as the
MRN complex, XPF/ERCC1, Mus81, SLX1/SLX4, CtIP and
ARTEMIS (Connelly & Leach, 2004; Eid et al, 2010; Hamilton &
Maizels, 2010; Nakamura et al, 2010; Pommier et al, 2006). Cell
cycle status and the choice of a particular nuclease can
subsequently influence the nature of the DNA break and the
mechanism of its repair. None of these nucleases has been
conclusively shown to play a part in the repair of Top1-linked
DNA single-strand breaks (Top1-SSBs). In contrast, these
nucleases have been shown to be involved in the repair of
Top1-linked DNA double-strand breaks (DSBs) (Shrivastav et al,





A heritable neurodegenerative disease that leads to severe disability
and increased risk of cancer. Ataxia is a lack of coordination of
muscle movements and telangiectasia refers to small dilated blood
vessels.
Camptothecin
A cytotoxic chemical derived from plants that binds to Top1 and DNA
resulting in a stabilized ternary complex, preventing DNA re-ligation. It
therefore causes DNA damage.
Double-strand break
A break or discontinuity in two strands of the DNA double helix.
Homologous recombination
A process in which nucleotide sequences are exchanged between two
homologous or identical molecules of DNA, leading to accurate repair of
harmful double-strand breaks.
Neuropathy
Damage to nerves of the peripheral nervous system.
Non-homologous end joining
A process in which DNA breaks are directly ligated without the need for a
homologous template.
Nucleotide excision repair
A DNA repair process by which cells can prevent unwanted mutations by
removing UV-induced DNA damage.
Relative microcephaly
A head size that falls within the normal range but is disproportionately
small when compared with the patient’s length or weight centiles.
Single-strand break
A discontinuity or a break in only one strand of the DNA double helix.
Somatotropic axis
An intricate network that controls metabolism and comprises of
hypothalamic regulatory centres, the anterior pituitary gland, peripheral
target organs, receptors and signalling molecules.
Topological modification
Alteration of the superhelical density of the DNA double helix: i.e. a change
in the number of links and knots in the DNA double helix.
Figure 1. The cerebellum is a common target for disorders with DNA repair
defects. Ataxia telagiectasia (AT), Spinocerebellar ataxia with axonal
neuropathy 1 (SCAN1), Ataxia oculomotor apraxia 1 (AOA1), and Ataxia
ocuolomotor apraxia 2 (AOA2) are DNA repair-related disorders that share
cerebellar degeneration as the most striking clinical feature. In contrast to AT
where patients present with immunodeficiency and cancer, symptoms of
SCAN1, AOA1 and AOA2 appear to be restricted to the nervous system.
It is interesting to note that there is some degree of overlap in the
extra-neurological features. Whereas AT and AOA2 patients present with high
levels of AFP, SCAN1 and AOA1 present with reduced levels of serum albumin.
This may reflect a consequence of the associated DNA repair defect or arise as
a result of progressive functional decline.
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template to repair the break by homologous recombination (HR)
or directly ligate the two DSB ends during non-homologous end
joining (NHEJ). It is worth noting that HR is absent in non-
cycling cells and thus NHEJ would be the prevailing pathway for
repair of DSBs.
Tyrosyl DNA phosphodiesterase 1 (TDP1)
In striking contrast to the nucleolytic cleavage of DNA to remove
‘stalled’ topoisomerases, cells employ another more accurate
and error-free repair mechanism, which involves the hydrolytic
cleavage of the covalent phosphotyrosyl bond linking the
topoisomerase to DNA termini. The prototype enzyme for such
an activity was first reported in yeast and named TDP1 (Yang
et al, 1996). The human homologue of the yeast enzyme was
subsequently reported and its defect was associated with defects
in the repair of topoisomerase 1 DNA breaks (El-Khamisy et al,
2005; Interthal et al, 2005a). The importance of this mode of
catalysis is highlighted by the human genetic, neurological
disease SCAN1, which is associated withmutations in TDP1 and
defects in the repair of Top1-SSBs induced by the Top1 poison
camptothecin (CPT), hydrogen peroxide or ionizing radiation
(El-Khamisy et al, 2005; Interthal et al, 2005a; Katyal et al, 2007;
Takashima et al, 2002). Unlike AT and AOA1, SCAN1 patients
identified to date possess a later onset (16 years) but they also
present with cerebellar atrophy and peripheral neuropathy. The
unique phosphodiesterase activity of TDP1 has also been
implicated in the repair of a variety of oxidative 30-termini, such
as 30-phosphoglycolate (Inamdar et al, 2002; Interthal et al,
2005b; Zhou et al, 2005, 2009). TDP1 also possesses a limited
RNA and DNA 30-nucleosidase activity, removing a single
nucleotide from the 30-hydroxyl terminus of the oligonucleotide
(Bahmed et al, 2010; Interthal et al, 2005b). More recently, the
corresponding activity that repairs Top2-mediated DNA breaks
was identified for the enzyme TTRAP and was subsequently
named TDP2 (Ledesma et al, 2009; Zeng et al, 2011). Whether
defects in TDP2 lead to neurological disorders in humans or
mice, and whether TDP2 contributes to the repair of Top1-
breaks remains to be determined.
What could be the source of TDP1-dependent breaks in
neurons? One of the most common causes of nicks in DNA is
oxidative attack by endogenous reactive oxygen species (ROS),
which produces, at least in the case of H2O2, more SSBs than
DSBs (Bradley & Kohn, 1979). It has been shown that nicks, gaps
and discontinuities in DNA can lead to the formation of Top1-
breaks (Pourquier et al, 1997). It is therefore plausible to
speculate that Top1-breaks arise endogenously in cells and that
TDP1 is required to deal with them. In addition, collision of
Top1 cleavage complexes with RNA polymerases can also lead
to Top1-breaks (Bendixen et al, 1990). Un-repaired DNA breaks
with damaged termini have been shown to block progression of
RNA polymerases in vitro (Bendixen et al, 1990) and thus could
provide a possible explanation for neuronal cell death in case of
defective TDP1. Another possible explanation for neuronal cell
death could be the accumulation of excessive DNA breaks in the
absence of TDP1 with subsequent over-activation of poly-(ADP)
ribose polymerases and the depletion of neural NADþ and ATP.
This may trigger neural cell death by apoptosis. Neural
mitochondria may play role in this mode of cell death via the
release of apoptosis-inducing factor (AIF) (see below).
Although TDP1-dependent repair is a housekeeping process
and TDP1 exists in a complex with the SSB-repair machinery via
interaction with DNA ligase III a(Lig3a) under unperturbed
culture conditions (El-Khamisy et al, 2005), the level of this
interaction might still be regulated. Central to this regulation is
its post-translational modification by phosphorylation, which
was first reported for TDP1 following DNA damage by the
Povirk laboratory, Department of Pharmacology and Toxicol-
ogy, Richmond, USA (Zhou et al, 2005). More recently, a serine
residue in the less conserved amino terminus domain of TDP1
(serine 81) was reported to mediate interaction with Lig3a
(Chiang et al, 2010) and the phosphorylation of this serine was
mediated by ATM or DNA PK (Das et al, 2009). Mutation of
TDP1 serine 81 to a residue that cannot be phosphorylated was
found to abrogate interaction with Lig3a in a yeast-two hybrid
analysis. This change has also resulted in a significant reduction
of TDP1 interaction with XRCC1/Lig3a as measured by co-
immunoprecipitation, when TDP1 was over-expressed in
mammalian cells (Chiang et al, 2010; Das et al, 2009).
What could be the biological significance of TDP1 phosphor-
ylation and/or interactionwith Lig3a? Phosphorylation of serine
81 has been shown to promote TDP1 stability following
exposure of cells to CPT (Chiang et al, 2010; Das et al, 2009).
TDP1 may be chaperoned by Lig3a, thereby increasing its
concentration at sites of damage to ensure completion of repair
and to prevent non-specific spurious DNA activities on un-
damaged DNA. Consistent with this notion, TDP1 phosphoryla-
tion at serine 81 facilitates its recruitment to sites of DNA
damage (Das et al, 2009). It is not clear whether this reflects
phosphorylation of serine 81 only or a subsequent requirement
for the interaction with Lig3a. The latter possibility seems
unlikely since Lig3a-deficient cells lack measurable nuclear
DNA repair defects (Chiang and El-Khamisy, unpublished
observations). It is thus possible that TDP1/Lig3a interaction
facilitates repair of Top1-SSBs at specific sites, such as clustered
DNA lesions. It is worth noting that Lig3a possesses an N-
terminal zinc finger (ZNF) domain homologous to that of
PARP1. This ZNF domain is believed to facilitate binding and
ligation of DNA breaks located near DNA secondary structures
(Cotner-Gohara et al, 2008; Taylor et al, 2000) and thus may be
important for targeting TDP1 to closely spaced Top1-SSBs.
Alternatively, the TDP1-Lig3a interaction may channel TDP1 to
an alternative NHEJ process to repair Top1-DSBs, for which a
role for Lig3a has been proposed (Audebert et al, 2004). It is also
possible that the interaction of TDP1 with Lig3a is dispensable
for nuclear DNA repair but critical for mitochondrial DNA
repair, for which both enzymatic activities have been observed
(see below).
Why do lower eukaryotes such as yeast not need the
N-terminus domain of TDP1? It is possible that higher eukaryotes
require more efficient mechanisms for repairing endogenous
Top1-breaks to keep their steady-state level below a certain
threshold. This may be particularly important in non-dividing
cells where cell death may be dictated by a much lower threshold
of DNA breaks within a specific cellular compartment. It is also
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possible that the evolutionary addition of the N-terminus domain
of TDP1 reflects the need for better orchestration of repair
processes due to bigger genome size and consequently the extent
of breaks arising per cell. It would be interesting to determine the
relative proportion of Top1-linked DNA breaks arising endogen-
ously in lower eukaryotes to that in human.
What is the relevance of TDP1 serine 81 to SCAN1? The
known SCAN1 patients possess a homozygous mutation
(H493R) within the active site of TDP1 that results in a 3-
fold reduction of expression, presumably due to instability of the
mutant protein. It is not known whether this instability is due to
improper folding of the mutant TDP1H493R protein. It is also not
known whether TDP1H493R can be efficiently phosphorylated at
S81 in vivo and whether this affects its steady-state level at
endogenous levels of DNA damage. Cell free assays utilizing
anti-TDP1 immunoprecipitates revealed no detectable TDP1
activity from SCAN1 lymphoblastoid cells (LCLs) and experi-
ments utilizing recombinant TDP1H493R protein or whole cell
extracts from SCAN1 cells revealed 25-fold or 100-fold reduction
of enzymatic activity, respectively (El-Khamisy et al, 2005;
Interthal et al, 2005a). It is worth noting that the mutant
TDP1H493R remains bound to the 30-terminus after releasing
Top1, but the relative proportion of Top1-linked breaks versus
TDP1-linked breaks in SCAN1 is not fully resolved (Hirano et al,
2007; Interthal et al, 2005a). Importantly, the relative impact of
TDP1-linked breaks versus Top1-linked breaks on neurological
function is not determined. Accumulation of the latter has been
associated with age-dependent reduction of cerebellar size in
Tdp1/mice (Katyal et al, 2007). Investigation of the impact of
TDP1-linked breaks on neurological function awaits the
generation of Tdp1H493R knock-in mice.
Polynucleotide kinase phosphatase (PNKP)
One of the most common forms of damaged DNA termini
induced by ROS is 30-phosphate, which is a major substrate for
polynucleotide kinase phosphatase (PNKP, Chen et al, 1991).
Importantly, the product of TDP1 activity is 30-phosphate and 50-
hydroxyl termini, both of which require the 30-phosphatase and
50-kinase activities of PNKP to create ligatable termini (Fig 2).
Mutations in PNKP were recently identified in several pedigrees
of Arabic and European origin that possess an autosomal
recessive disorder, which features microcephaly, infantile-onset
seizures, and developmental delay denoted MCSZ (Shen et al,
2010). Similar to SCAN1, MCSZ patients had no reported
evidence for increased cancer predisposition or immunodefi-
ciency. However, in an intriguing contrast to SCAN1, MCSZ
patients lack ataxia ‘lack of muscle coordination’ and cerebellar
degeneration. Western blotting and RT-PCR analyses of cells
from the affected individuals suggest a correlation between the
severity of clinical symptoms and expression/activity of PNKP
(Shen et al, 2010). Consistent with a role for PNKP in the repair
of Top1-mediated breaks, A549 cells depleted for PNKP (El-
Khamisy et al, 2005) or LCLs from MCSZ patients (Shen et al,
2010) accumulate higher levels of CPT-induced DNA breaks,
compared to control cells. More importantly, LCLs from MCSZ
patients repair hydrogen peroxide-induced damage at a much
lower rate than normal cells (Shen et al, 2010). It is worth noting
that through its fork head associated (FHA) domain, PNKP
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Figure 2. Repair of topoisomerase-mediated DNA damage and
neurodegeneration: same pathway with different clinical features. Stalled DNA
topoisomerase 1 (Top1) is subjected to proteasomal degradation to form a
smaller peptide that is then acted upon by TDP1. TDP1 cleaves the
phosphodiester bond between Top1 peptide and DNA, creating 30-phosphate
and 50-hydroxyl termini. In preparation for ligation, PNKP restores
conventional 30-hydroxyl and 50-phosphate termini, followed by sealing the
nick by a DNA ligase. Mutations in CUL4B (involved in proteasomal
degradation) underlie defects in the degradation step of DNA topoisomerase 1
repair, causing mental retardation and motor neuron impairment in XLMR.
Defects in the downstream step catalysed by TDP1 causes cerebellar
degeneration and peripheral neuropathy typified by patients with SCAN1.
Mutations in PNKP underlie microcephaly and seizures observed in MCSZ.
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interacts with XRCC1 or XRCC4, components of the single- and
double-strand break repair machinery (Chappell et al, 2002;
Jilani et al, 1999; Karimi-Busheri et al, 1999; Whitehouse et al,
2001).
Although the ultimate outcome of TDP1 deficiency is similar
to PNKP deficiency, resulting in neuronal cell loss, the cause of
this cell loss is likely to be fundamentally different, causing
cerebellar degeneration in SCAN1 and microcephaly in MCSZ
(Shen et al, 2010). Microcephaly results from proliferation
defects or cell loss during neurogenesis. This could result from
DNA damage interfering with replication or during the
differentiation of neuron progenitors. Mouse models for LIG4,
ATR and BRCA2 point at profound apoptosis during neuronal
development, resulting in microcephaly (Barnes et al, 1998;
Frappart et al, 2007;Murga et al, 2009).Whether PNKPdeficiency
in mice will also result in microcephaly is yet to be tested.
Cullin 4B
Cullin 4B is an E3-ubiquitin ligase that is encoded by the CUL4B
gene and controls a variety of DNA repair processes. Mutations
in CUL4B have been recently associated with mental and growth
retardation, relative microcephaly and motor neuron impair-
ment; a syndrome called X-linked mental retardation (XLMR)
(Cabezas et al, 2000; Tarpey et al, 2007; Zou et al, 2007, 2009).
In contrast to SCAN1, Cul4B-mutated patients do not present
with cerebellar atrophy, however they develop gait ataxia with
increasing age (Cabezas et al, 2000; Tarpey et al, 2007; Zou et al,
2007, 2009). LCLs from CUL4B-patients and siRNA knockdown
of CUL4B in A549 cells exhibit CPT sensitivity (Kerzendorfer
et al, 2010), pointing to a role for Cullin 4B in the repair of Top1-
mediated DNA damage. Consistent with these observations,
Top1 degradation following CPT damage was significantly
impaired in CUL4B-mutated LCLs compared to wild-type cells.
Since cellular and cell-free assays using recombinant proteins
have shown that proteasomal degradation of Top1 to a small
peptide is a prerequisite for TDP1 action (El-Khamisy et al, 2007;
Interthal et al, 2001), the increased sensitivity of CUL4B-mutated
LCLs to CPT points to a role for Cullin 4B upstream of TDP1
(Fig 2). This notion was reinforced by the work of Kerzendorfer
et al, who showed increased levels of CPT-induced DNA breaks
in CUL4B-mutated LCLs compared to wild-type cells (Kerzen-
dorfer et al, 2010). The authors employed a modified version of
the alkaline comet assay to measure Top1-cleavage complexes
and thus events upstream of TDP1. It is likely that the impaired
degradation of Top1 results in accumulation of protein-linked
breaks that will interfere with transcription, causing the specific
neuronal involvement in CUL4B-mutated patients. Whether
CUL4B deficiency in mice will also result in growth and mental
retardation is yet to be tested.
REPAIR OF ABORTIVE LIGATION PRODUCTS AND
NEURODEGENERATION
Aprataxin
Aprataxin (APTX) is mutated in AOA1 which is an autosomal
recessive spinocerebellar ataxia that shares the neurological
features of AT but lacks the non-neurological features such as
immunodeficiency and cancer predisposition. AOA1 accounts
for approximately 10% of all autosomal recessive cerebellar
ataxias (Le Ber et al, 2003). AOA1 patients present with
cerebellar atrophy, ataxia and oculomotor apraxia (limited eye
movement after instruction), hypoalbuminaemia, hypercholes-
terolaemia and involuntary muscle movements (Date et al,
2001; Moreira et al, 2001).
Aprataxin is a member of the histidine triad (HIT) domain
superfamily of nucleotide hydrolases/transferases. It possesses a
divergent FHA domain at the N-terminus, similar to PNKP. The
FHA domain of APTXmediates its interactionwith casein kinase 2
(CK2) phosphorylated XRCC1 or XRCC4 (Clements et al, 2004; Iles
et al, 2007; Koch et al, 2004). In addition, APTX has been shown to
associate with the nucleolar proteins nucleolin, nucleophosmin
and upstream binding factor (UBF1, Becherel et al, 2006; Gueven
et al, 2004). This may reflect a requirement for APTX at sites of
high transcriptional demand. It would be interesting to examine
the effect of APTX deletion on gene expression under conditions of
high transcriptional activity or elevated oxidative stress.
Consistent with a requirement for APTX activity for
neurological function, most of the mutations identified to date
in AOA1 are located within or in very close proximity to the HIT
domain. The impact of these mutations on the function of APTX
seems to correlate well with clinical features (Seidle et al, 2005;
Tranchant et al, 2003). Consistent with possessing a HIT
domain, APTX can release AMP from AMP-lysine, albeit with
low catalytic activity (Kijas et al, 2006). APTX has also been
reported to process 30-phosphate and 30-phosphoglycolate
termini, but again with low catalytic activity (Takahashi et al,
2007). APTX activity is much higher for AMP linked to 50-DNA
termini (Ahel et al, 2006; Rass et al, 2007a), raising the
possibility that DNA lesions with 50-AMP termini are the
physiological substrate for APTX in cells. These structures are
normal intermediates of DNA ligation and the prediction is that
an incomplete ligation cycle may lead to the formation of DNA
lesions with 50-AMP, for which APTX is needed to remove the
AMP and re-set the ligase (Rass et al, 2007b). Incomplete
‘premature’ ligation is likely to happen if the ligase binds to DNA
and transfers the AMP to the 50-terminus before 30-end
processing has occurred. This notion has been supported by
observations in mouse astrocytes (El-Khamisy et al, 2009) and
in yeast (Daley et al, 2010), where co-deletion of APTX together
with enzymes that process 30-damaged termini had synergistic
defect in the ability of cells to repair oxidative DNA damage.
Why does APTX deficiency lead to neuronal cell death?
Studies on cultured mammalian cells revealed little impact of
the loss of APTX alone on cellular DNA repair capacity, with
variations in the extent of this impact depending on the
experimental read out adopted and the type of cells employed
(Becherel et al, 2006; Clements et al, 2004; Gueven et al, 2004,
2007; Harris et al, 2009; Mosesso et al, 2005; Reynolds et al,
2009). This likely reflects the low frequency of formation of
APTX-dependent lesions and suggests that neuronal cell death
recurs due to stochastic accumulation of these lesions over
years. Un-repaired 50-AMP breaks could interfere with cellular
transcription and may affect global gene expression. Consistent
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with this, a recent study by the Lavin laboratory (Radiation
Biology and Oncology Laboratory, Queensland, Australia)
showed reduced expression of PARP-1, apurinic endonuclease
1 (APE1) and OGG1 in AOA1 cells (Harris et al, 2009). Based on
the assumption that a DNA ligase dissociates ‘falls off’ after
transferring the AMP to the 50-DNA terminus, in vitro studies
with 50-AMP synthetic substrates revealed no inhibitory effect of
the 50-AMP on the repair of the 30-terminus by PNKP or on the
addition of one nucleotide by DNA polymerase b (POLb)
(Reynolds et al, 2009). It is worth noting that these experiments
uncouple two steps of the ligation cycle that may not be
uncoupled in vivo and thus whether this will also be true in the
context of a full ligation cycle in cells is yet to be tested. It has
also been proposed that APTX loss is associated with defects in
DNA ligation, which could be overcome by addition of non-
adenylated DNA ligase (Reynolds et al, 2009), raising the
intriguing possibility that cellular levels of ATP may determine
the frequency of 50-AMP lesions. If this is true then identification
of small molecules that promote de-adenylation of DNA ligase
could potentially reverse the abortive DNA ligase step that
creates 50-AMP breaks and thus circumvent the requirement for
APTX. Since the most likely endogenous cause of 50-AMP breaks
in cells lacking APTX is ROS, it would be interesting to study the
role of APTX under conditions of elevated oxidative stress. If it is
true that oxidative stress is an important aetiological factor for
the neuropathology, will antioxidants be effective at preventing
cell loss? The use of animal models will be critical in resolving at
least some of these issues and will further our understanding of
the associated neuropathology.
Cycling cells possess mechanisms that could deal with APTX-
dependent breaks that are absent in non-cycling cells. For
example, the use of a homologous template for the repair of
DNA damage during HR or the use of replicative DNA
polymerases to extend the 30-terminus, creating a 50-AMP flap
that could be clipped off by FEN1, circumventing the
requirement for APTX. Evidence for the latter possibility was
supported by studies in mammalian cells and in yeast (Daley
et al, 2010; Reynolds et al, 2009). However, the reason that
APTX deficiency specifically affects the cerebellum is far more
challenging and is yet to be explained.
Mitochondrial dysfunction and neurological disorders
Mitochondria are tiny, lozenge-shaped, semi-autonomously
reproductive organelles within eukaryotic cells that carry their
own genetic material, the mitochondrial genome (mtDNA).
Mitochondria contain between 2 and 10 copies of mtDNA and
the most conservative estimate suggests that each eukaryotic
cell contains more than 100 mitochondria (Elson & Lightowlers,
2006; Holt et al, 2007). This can vary considerably according to
the energy demands of a given tissue. For example, neuronal
cells have many thousands of mitochondria. The expression of
two tissue-specific mitochondrial proteins Erra and Gabpa/b
appear to control the number of mitochondria in a given tissue
(Thorburn, 2004). mtDNA is very susceptible to DNA damage
due to its unique nature and location within the cell. The
mitochondria produce most of the cell’s ROS and mtDNA is
located on the inner membrane close to the sites of ROS
production, rendering mtDNA particularly vulnerable to DNA
damage. In addition, mtDNA lacks protective histones and is
almost exclusively transcribed (contains very few non-coding
areas). This is in marked contrast to nuclear DNA, where coding
genes are interrupted by introns and less than 2% is expressed.
It is thus critical to maintain the genomic stability of mtDNA, as
it controls many functions important for cell viability, such as
energy production, production of ROS and regulation of
apoptosis. For example, it is estimated that mitochondria
generate 65 kg of ATP every day (Lane, 2006). Association of
human disease and mitochondrial dysfunction is well estab-
lished (Bishop et al, 2010; Calvo &Mootha, 2010;Westly, 2010).
The association between defects in mtDNA and human disease
was first reported in 1988 (Holt et al, 1988). Not surprisingly,
defects in the repair of breaks in mtDNA are expected to elicit
greater impact on tissues with high energy demands, such as the
brain (Lightowlers, 1992). Indeed, mitochondrial dysfunction
has been associated with a variety of human neurological
disorders, such as Alzheimers disease (Bonilla et al, 1999;
Cortopassi & Arnheim, 1990; Gredilla et al, 2010), Parkinsons
(Barroso et al, 1993; Orth & Schapira, 2002; Sherer et al, 2002),
Huntington (Panov et al, 2002), Friedreich’s ataxia (Tan et al,
2001), and Amyotrophic lateral sclerosis (Wong et al, 1995).
Detailed coverage of the relevance of mitochondrial organiza-
tion and repair to human disease was recently reviewed (Boesch
et al, 2010).
Currently, the understanding of nuclear–mitochondrial
interactions is limited and roles for mtDNA repair proteins
remain contentious. For example, mtDNA has no capacity for
independent replication and relies on nuclear-encoded DNA
polymerase gamma. In addition, several components of the
DNA repair machinery possess mitochondrial versions that are
also encoded by nuclear genes (Maynard et al, 2010; Roberts
et al, 2008; Weissman et al, 2007). For example, Lig3a, APE1,
APE2 and Cockayne syndrome B (CSB) have been shown to
localize to the mitochondria (Aamann et al, 2010; Chattopad-
hyay et al, 2006). Based on estimates of the number of
mitochondrial genes residing in the nuclear genome, around a
tenth of the population may be carrying genetic disorders that
could affect mitochondrial function (Thorburn, 2004). In this
context, mitochondrial DNA repair defects could contribute to
the neurological decline in some of the diseases discussed
above. For example, an APTX version with a putative
mitochondrial targeting sequence has been reported (Caldecott,
2008). Whether this specific isoform targets APTX to mitochon-
dria and, more importantly, whether it exists in cells and thus
could contribute, at least in part, to the neurological decline in
AOA1 is not clear. Whether the role of APTX in the
mitochondria, if any, is due to its DNA related functions or
due to novel RNA processing activities is not tested. Defects of
mtRNA maturation have been recently associated with an
autosomal recessive spastic ataxia with optic atrophy, high-
lighting the importance of RNA integrity for mitochondrial
function (Crosby et al, 2010).
TDP1 activity was recently identified in the kinetoplastid
parasite Leishmania donovani (Banerjee et al, 2010), in
mitochondria of MCF-7 human carcinoma cells (Das et al,
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2010), and in the mitochondria of murine neurons (our
unpublished observations). Since mtDNA is subject to oxidative
DNA damage, some of which may be substrates for TDP1
activity, and because the mitochondria possess a specific
mtTop1 isoform that can form Top1-DNA covalent adducts in
mtDNA (Zhang & Pommier, 2008), it is sensible for the
mitochondria to possess TDP1 activity to deal with endogenous
levels of DNA breaks. These observations suggest that nuclear-
encoded TDP1 is translocated to themitochondria. However, we
and others have failed to detect a mitochondrial targeting
sequence in TDP1, suggesting the presence of novel importers or
a specific mitochondrial isoform. It is possible that a TDP1
activity was encoded by mtDNA and has moved from the
mitochondria to the nucleus during evolution. A more efficient
way for repairing DNA damage in mitochondria is likely to be
through moving a pool of nuclear repair proteins rather than
inducing the expression of mtDNA genes encoding for the repair
proteins. Tracking down genes that have shifted to the nucleus
may elucidate important connections to human disease. The
physiological importance of TDP1 in the mitochondria was
recently suggested by a polymerase chain reaction-based assay
to measure mtDNA repair in Tdp1/ mouse embryonic
fibroblasts (Das et al, 2010). The results suggest a slower rate
of repair of hydrogen peroxide-induced DNA damage in mtDNA
in Tdp1/ cells compared to wild-type control cells. Whether
mtDNA of SCAN1 or Tdp1/ neuronal cells accumulate
damage, mutations or deletions with age is not clear.
DNA repair and physiological aging
Why is a rodent old at 3 years and a human old at 80 years?
This difference reflects the rapidity of the aging process, which is
a syndrome of changes that are irreversible, progressive, and
multi-faceted. Damage-associated aging can occur in all
biomolecules including DNA, proteins and lipids, affecting
different cells and organs. Aging changes are often associated
with increased mortality rates. It is thus important to identify
aging changes, which are not associated with a specific aging-
related disorder, and as such could be used as biomarkers of
normal ‘physiological’ aging. These biomarkers would be better
predictors of the increased likelihood of mortality. There are
several proposed aging biomarkers but, as yet, none has been
validated and widely accepted.
Aging is regulated by the extent of stochastic damage that
accumulates over time and the rate at which this damage
accumulates (Kirkwood & Holliday, 1979). The latter is dictated
by the efficiency of genetic pathways that control longevity
(Holzenberger et al, 2003; Kurosu et al, 2005). Mitochondrial
function is a key player in these mechanisms. This was first
suggested in Drosophila (Miquel et al, 1983) and subsequently
in mammals where age-dependent accumulation of mutations
within mtDNA was reported (Lee et al, 1999; Michikawa et al,
1999). DNA deletions have also been shown to cause premature
aging in mitochondrial mutator mice (Vermulst et al, 2008). The
link between DNA damage/repair and aging is also rapidly
emerging (Fig 3) and was first highlighted by the premature
aging-like syndromes that are associated with defects in DNA
repair, such as defects in nucleotide excision repair (NER,
Hasty et al, 2003). The inability to repair bulky DNA lesions
from the transcribed strand of DNA through transcription-
coupled repair is associated with the progeroid symptoms
observed in Cockayne syndrome (CS) and trichothiodystrophy
(TTD, Lehmann, 2003; Niedernhofer et al, 2006). Prolonged
treatment of mice with DNA damaging agents leads to down-
regulation of genes that are normally associated with the
extension of life span, such as insulin-like growth factor 1
(IGF-1) and growth hormone (GH, Niedernhofer et al, 2006). It is
possible that attenuation of the somatotropic axis is an indirect
consequence of tissue damage induced by the accumulation of
DNA damage. There is evidence that accumulation of DNA
damage can lead to age-dependent changes in DNA repair
Review
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Figure 3. Themitochondrial dysfunction, DNA damage, and aging triangle.
Accumulation of mutations with age has been extensively studied in mice and
humans as one cause of ‘physiological’ aging. DNA damage can also cause
downregulation of genes that are normally associated with the extension of
life span, such as IGF-1 and GH, contributing to the aging process. On the other
hand, aging leads to reduced expression of DNA repair factors, leading to
increased accumulation of DNA damage. Aging also may cause reduced
trafficking of DNA repair factors to the mitochondria, contributing to
mitochondrial dysfunction. The latter results in defects in the oxidative
phosphorylation leading to increased production of ROS and consequent
accumulation of DNA damage in mtDNA. This vicious cycle can potentially be
broken by counteracting any of its components. For example, enhancing DNA
repair by the use of small molecule based approaches or gene therapy may
reduce the extent of DNA damage. Anti-oxidants and caloric restriction may
reduce the extent of mitochondrial dysfunction and delay the symptoms of
aging.
84  2011 EMBO Molecular Medicine EMBO Mol Med 3, 78–88 www.embomolmed.org
(Moriwaki et al, 1996; Gorbunova et al, 2007). Alternatively, it
could represent a direct response to specific types of DNA
lesions. Evidence for the latter is supported by the observation
that accumulation of transcription-blocking lesions directly
causes attenuation of the somatotropic axis in aging animals
(Garinis et al, 2009). Since a defect in the repair of Top1-
associated breaks leads to stalled transcription, it is intriguing to
speculate that efficiency of this repair process correlates with the
aging process. This could include the proteasomal degradation
of Top1, the removal of the remaining Top1 peptide by TDP1, or
the restoration of conventional 30-hydroxyl and 50-phosphate
termini by PNKP. Mouse models lacking these components will
be a invaluable resource to test this hypothesis.
CONCLUSIONS
The unique structure of the nervous system requires the
interplay of distinct but vigilant DNA repair processes to deal
with different forms of DNA damage. Defects in these processes
have been broadly linked to aging, neurodegeneration and
mitochondrial dysfunction. More recently, accumulating evi-
dence suggests that specific defects in processing damaged DNA
termini underlie neurological decline. In addition to the
examples discussed above, oxidative stress and the relative
availability of 50-end processing activities have also been
implicated in the expansion of triplet repeats in Huntington
disease (Goula et al, 2009; Kovtun et al, 2007). Further studies
are clearly needed to address many unresolved questions. For
example, what is the threshold of DNA breaks that trigger cell
death in neural cells and how is this compared to other cells?
How do unrepaired breaks lead to neuronal dysfunction? What
is the relative contribution of mitochondrial and nuclear DNA
repair in the extent of neurological dysfunction? It is worth
noting that brain specific deletion of the ‘nuclear’ scaffold
protein XRCC1 leads to cerebellar defects in mice (Lee et al,
2009). Do mitochondria require similar scaffolding factors?
What is the relative proportion of physiological levels of nuclear
and mitochondrial Top1-linked breaks? Do mitochondria
possess their own version of TDP1, TDP2 and PNK? Why isn’t
human DNA ‘programmed’ to re-grow neural cells as it ages?
Mouse model systems will be invaluable resources to shed light
on some of these crucial issues.
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